America First Legal (AFL) has taken legal action against the Food and Drug Administration in an effort to obtain records from the Biden administration regarding the use of puberty blockers for children. The lawsuit, filed on Friday, aims to reveal the government’s internal guidance on the controversial issue.

According to AFL, the FDA was aware of the mental health risks associated with puberty blockers but still recommended their approval for children. The Trump-aligned legal group previously uncovered communications from the former administration through a Freedom of Information Act (FOIA) request, which shed light on the FDA’s knowledge of the risks.

Despite acknowledging the federal information request, the FDA has not cooperated with AFL’s follow-up FOIA request for documents specifically related to the agency’s internal guidance on the off-label use of puberty blockers. The deadline for the FDA to produce the documents has passed.

Exposing the Truth

“The Biden administration pushed gender-denying treatments on American kids. Now it’s time to expose what officials really knew,” said AFL counsel Will Scolinos.

In a similar situation, AFL had to engage in litigation to compel the release of documents from the Biden-era Division of General Endocrinology at the FDA. These documents revealed that despite the known risks of puberty blockers, the agency recommended their approval for children.

Studies have shown that puberty blockers can increase the risk of depression, suicidality, and seizure in children. An FDA official from the endocrinology division was quoted in uncovered emails stating that there is a need for these drugs in gender transition, despite the risks.

Supporting Evidence

Research conducted at the University of Texas found that patients with gender dysphoria, including those who underwent gender-change surgery, experienced increased rates of depression and anxiety. The study emphasized the importance of gender-sensitive mental health support for these individuals.

Male patients who received surgery had significantly higher rates of depression and anxiety compared to those who did not undergo surgery. The same pattern was observed among female patients as well.

Fox News Digital reached out to the FDA for comment but has not received a response at this time.

This article was contributed by Fox News’ Melissa Rudy and Michael Dorgan.